Robert Burns, MD
Pain Medicine · Pascagoula, MSNPI 1720179401
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $506 and has fallen 85.6% since, to $73 in 2025. That places this record below the midpoint for pain medicine clinicians in MS, where the typical reported total is $3,332.
Across 109 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$266
- AstraZeneca$203
- Novo Nordisk$203
- GSK$191
- Pfizer$159
- Sanofi-aventis U.S. LLC$145
- plus $993 from 20 others
What the payments were for
- Food & beverage$2,156100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $266 |
| AstraZeneca | 10 | $203 |
| Novo Nordisk | 13 | $203 |
| GSK | 5 | $191 |
| Pfizer | 11 | $159 |
| Sanofi-aventis U.S. LLC | 9 | $145 |
| Melinta Therapeutics, LLC | 1 | $117 |
| Alkermes, Inc. | 1 | $111 |
| Corcept Therapeutics | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $69 |
| Kowa Pharmaceuticals America, Inc. | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $62 |
| Boehringer Ingelheim | 4 | $58 |
| Astellas Pharma US Inc | 3 | $51 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $51 |
| AbbVie(2 entities) | 2 | $40 |
| Medtronic | 2 | $36 |
| Abbott | 2 | $35 |
| ALON Medical Technology | 1 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Amgen | 2 | $32 |
| Exact Sciences | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Inari Medical, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$445
- SHINGRIX$122
- Kimyrsa$117
- ARISTADA INITIO$111
How this compares
$2,158 in reported general payments places this provider in the 40th percentile of 48 pain medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $44,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $29,146 |
| TrulicityDulaglutide | 11 | $24,329 |
| MounjaroTirzepatide | 11 | $22,545 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $17,627 |
| MyrbetriqMirabegron | 19 | $16,510 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $15,817 |
| LinzessLinaclotide | 12 | $14,784 |
| EliquisApixaban | 25 | $14,702 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $13,308 |
| FarxigaDapagliflozin Propanediol | 24 | $12,511 |
| XareltoRivaroxaban | 13 | $12,042 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $11,299 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,530 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 530 | $10,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $266 | $46,87422 claims |
| Novo NordiskOzempic | $203 | $44,65329 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $191 | $39,67649 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $16,51019 claims |
| AbbVieLinzess | $40 | $14,78412 claims |
| PfizerEliquis | $159 | $14,70225 claims |
| AstraZenecaFarxiga | $203 | $12,51124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $69 | $4,98111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,855233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 48 pain medicine providers in Mississippi.
Other pain medicine in Pascagoula
- Rayhan TariqLaurel$64K
- Alan TorreyVicksburg$30K
- Landon BurnsFlowood$22K
- Joe CookByram$21K
- Bretley SitzmanHattiesburg$18K
- Michael ScarbroughCorinth$15K
- Casey OrzechowiczJackson$15K
- Anand PremJackson$13K
- Rex WilliamsStarkville$12K
- Jeremy SmithermanFlowood$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.